Propofol and ketoconazole interaction in dogs: prolonged recovery warning
Published: · Updated:
Ketoconazole is named in a dog-label warning about reduced propofol clearance and prolonged recovery. No universal washout interval is established.
Short answer
The Propodine label names ketoconazole in a warning about reduced propofol clearance and prolonged recovery, referring to CYP2B11 in the dog. The passage gives no universal washout interval or fixed dose adjustment. Its dog-specific enzyme statement should not be presented as a directly demonstrated finding in cats. [1]
Compare the evidence
| Source and design | Population or scope | Finding | Limits |
|---|---|---|---|
| Official Propodine label [1] | Dog CYP2B11 interaction passage | Names ketoconazole in reduced propofol clearance and prolonged recovery. | No pair-specific recovery duration, fixed correction or universal washout interval; not direct cat evidence. |
| Martinez et al., 2024 — recombinant enzyme experiments [2] | Canine P450 oxidoreductase variants and CYP2B11 | Certain variants reduced propofol oxidation; in vivo confirmation was still needed. | Did not test ketoconazole co-administration, clinical recovery time or a breed-specific withholding interval. |
Can ketoconazole affect recovery after propofol in dogs?
Yes. Propodine names ketoconazole in a warning about reduced propofol clearance and prolonged recovery, referring specifically to dog CYP2B11. Include ketoconazole in the medication history provided to the anesthesia team. [1]
What does reduced clearance mean in this warning?
It means slower propofol elimination in the interaction context described. The passage gives no patient-specific recovery prediction or number of additional minutes, and does not establish that every exposed dog will recover slowly. [1]
Does the label establish a standard propofol dose reduction?
No fixed ketoconazole-related correction is supplied. Propodine describes titration to individual response and separately notes altered requirements with sedatives and analgesics. The veterinary team must assess these effects within the complete anesthetic plan. [1]
Should ketoconazole always be withheld for a fixed number of days?
The cited warning specifies no universal ketoconazole washout interval. Report what was administered and when; the veterinary team must decide whether medication or procedure timing needs changing for that dog. [1]
Could other anesthetic medicines explain a prolonged recovery?
Yes. Propodine discusses prolonged recovery with some opioid infusions and separate respiratory and heart-rate effects. A delayed recovery needs assessment of the complete regimen; a matching ketoconazole pair does not establish causation. [1]
Does a label for dogs and cats prove this enzyme interaction in cats?
No. The particular enzyme passage identifies dogs, despite the product's wider species authorization. The qualifying record is also dog-scoped. It should not be presented as a directly demonstrated feline interaction. [1]
Evidence appraisal
The direct clinical warning is in Propodine: medicines including ketoconazole are named in a passage on reduced propofol clearance and prolonged recovery, with CYP2B11 identified in the dog. The label passage provides neither a pair-specific recovery-time distribution nor a fixed dose correction. Its dog-specific enzyme wording must not be broadened to feline evidence merely because the product is authorized for both species. [1]
Related experimental work illustrates the limits of mechanistic inference. Martinez and colleagues’ 2024 study found that certain canine P450 oxidoreductase variants reduced CYP2B11-mediated propofol oxidation in a recombinant system, with in vivo confirmation still needed. The experiment did not test ketoconazole co-administration or establish a breed-specific washout time. It adds enzyme-level context without independently proving the clinical size of this drug interaction. [2]
Clinical interpretation and follow-up
The AAHA anesthesia guidelines place review across preparation, anesthesia and recovery. Propodine separately notes changed requirements with sedatives or analgesics and respiratory or heart-rate effects with opioids. Reduced clearance, induction requirement and cardiorespiratory depression need distinct assessment within that plan. [3] [1]
Record ketoconazole administrations, other sedatives or analgesics, intended technique and previous recovery concerns. Delayed recovery is an observation requiring assessment, not proof of a ketoconazole effect. Neither the label nor the enzyme experiment supplies a universal withholding interval or automatic dose adjustment. [1] [2]
Questions for veterinary review
Editorial discussion checklist for your veterinarian:
- Give the anesthesia team the ketoconazole product, route and recent administration history.
- Review other sedatives, analgesics and the intended anesthetic regimen before interpreting a single-pair warning.
- Do not infer a universal washout time, induction dose or recovery duration from this source.
Catalogue review status and evidence limits
The catalogue records contain verified direct evidence (dog): a species-scoped official-label statement, not necessarily a controlled interaction trial. The linked label PDF was also checked for publication.
A verified warning does not establish an individual animal's outcome, a patient-specific dose or independent clinical review. No matching rule does not prove safety.
Evidence sources
Citation scope: official labels support the interaction warnings; research and guidelines provide separately identified context. Each citation shows its document version or literature type and review scope. Catalogue identifiers may refer to earlier versions; this article uses the linked label PDF. Repeated labels are not independent studies. Source URLs and product authorizations may change.
- VMD: Propodine 10 mg/ml Emulsion for Injection/Infusion for Dogs and Cats — Summary of Product Characteristics
Evidence type: Official product label. Unlimited renewal September 2023. 4.8, interactions; 4.9, intravenous administration. Page 4, Page 5. Source checked: . Open official VMD source
- Pharmacogenomics of poor drug metabolism in greyhounds: Canine P450 oxidoreductase genetic variation, breed heterogeneity, and functional characterization.
Martinez SE et al. PLoS One. 2024;19(2):e0297191. Evidence type: Primary study. Review scope: Full text. Source checked: . Open research source
- 2020 AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats.
Grubb T et al. J Am Anim Hosp Assoc. 2020;56(2):59-82. Evidence type: Consensus guideline. Review scope: Abstract and bibliographic record. Source checked: . Open research source
Content responsibility: ZooDDI. For veterinary discussion, not diagnosis, prescribing or emergency care. No independent veterinary clinical review has been completed.